Relmada Therapeutics, Inc. – ‘10-K’ for 12/31/21 – ‘ZIP’

On:  Friday, 3/25/22, at 7:53am ET   ·   For:  12/31/21   ·   Accession #:  1213900-22-15012   ·   File #:  1-39082

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    792K 
 2: EX-23.1     Consent of Marcum LLP                               HTML     16K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     20K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     20K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     17K 
 6: EX-32.2     Certification -- §906 - SOA'02                      HTML     17K 
12: R1          Document And Entity Information                     HTML     87K 
13: R2          Consolidated Balance Sheets                         HTML    102K 
14: R3          Consolidated Balance Sheets (Parentheticals)        HTML     35K 
15: R4          Consolidated Statements of Operations               HTML     54K 
16: R5          Consolidated Statements of Changes in               HTML     61K 
                Stockholders? Equity                                             
17: R6          Consolidated Statements of Cash Flows               HTML     86K 
18: R7          Business                                            HTML     21K 
19: R8          Summary of Significant Accounting Policies          HTML     47K 
20: R9          Prepaid Expenses                                    HTML     22K 
21: R10         Fixed Assets                                        HTML     24K 
22: R11         Accrued Expenses                                    HTML     23K 
23: R12         Stockholders' Equity                                HTML     68K 
24: R13         Income Taxes                                        HTML     36K 
25: R14         Commitments and Contingencies                       HTML     35K 
26: R15         Related Party Transactions                          HTML     22K 
27: R16         Other Postretirement Benefit Plan                   HTML     24K 
28: R17         Subsequent Events                                   HTML     21K 
29: R18         Accounting Policies, by Policy (Policies)           HTML     82K 
30: R19         Summary of Significant Accounting Policies          HTML     22K 
                (Tables)                                                         
31: R20         Prepaid Expenses (Tables)                           HTML     22K 
32: R21         Fixed Assets (Tables)                               HTML     23K 
33: R22         Accrued Expenses (Tables)                           HTML     22K 
34: R23         Stockholders' Equity (Tables)                       HTML     49K 
35: R24         Income Taxes (Tables)                               HTML     30K 
36: R25         Commitments and Contingencies (Tables)              HTML     20K 
37: R26         Summary of Significant Accounting Policies          HTML     43K 
                (Details)                                                        
38: R27         Summary of Significant Accounting Policies          HTML     25K 
                (Details) - Schedule of anti-dilutive securities                 
39: R28         Prepaid Expenses (Details) - Schedule of prepaid    HTML     28K 
                expenses                                                         
40: R29         Fixed Assets (Details)                              HTML     20K 
41: R30         Fixed Assets (Details) - Schedule of fixed assets   HTML     28K 
42: R31         Accrued Expenses (Details)                          HTML     19K 
43: R32         Accrued Expenses (Details) - Schedule of accrued    HTML     31K 
                expenses                                                         
44: R33         Stockholders' Equity (Details)                      HTML    263K 
45: R34         Stockholders' Equity (Details) - Schedule of        HTML     66K 
                changes in options outstanding                                   
46: R35         Stockholders' Equity (Details) - Schedule of        HTML     32K 
                weighted average fair value of options                           
47: R36         Stockholders' Equity (Details) - Schedule of the    HTML     39K 
                changes in outstanding warrants                                  
48: R37         Stockholders' Equity (Details) - Schedule of        HTML     25K 
                stock-based compensation expense                                 
49: R38         Income Taxes (Details)                              HTML     26K 
50: R39         Income Taxes (Details) - Schedule of deferred tax   HTML     38K 
                assets                                                           
51: R40         Income Taxes (Details) - Schedule of                HTML     35K 
                reconciliation of the statutory tax rate to the                  
                effective tax rate                                               
52: R41         Commitments and Contingencies (Details)             HTML     58K 
53: R42         Commitments and Contingencies (Details) - Schedule  HTML     21K 
                of future minimum lease payments to be received                  
54: R43         Related Party Transactions (Details)                HTML     32K 
55: R44         Other Postretirement Benefit Plan (Details)         HTML     21K 
56: R45         Subsequent Events (Details)                         HTML     41K 
59: XML         IDEA XML File -- Filing Summary                      XML    104K 
57: XML         XBRL Instance -- f10k2021_relmadatherap_htm          XML    679K 
58: EXCEL       IDEA Workbook of Financial Reports                  XLSX     73K 
 8: EX-101.CAL  XBRL Calculations -- rlmd-20211231_cal               XML     65K 
 9: EX-101.DEF  XBRL Definitions -- rlmd-20211231_def                XML    546K 
10: EX-101.LAB  XBRL Labels -- rlmd-20211231_lab                     XML   1.09M 
11: EX-101.PRE  XBRL Presentations -- rlmd-20211231_pre              XML    544K 
 7: EX-101.SCH  XBRL Schema -- rlmd-20211231                         XSD    148K 
60: JSON        XBRL Instance as JSON Data -- MetaLinks              271±   369K 
61: ZIP         XBRL Zipped Folder -- 0001213900-22-015012-xbrl      Zip    202K 

‘ZIP’   —   XBRL Zipped Folder — 0001213900-22-015012-xbrl

This is an XBRL Zipped Folder.

	Download this zipped .zip folder
Files:	f10k2021_relmadatherap.htm f10k2021ex23-1_relmada.htm f10k2021ex31-1_relmada.htm f10k2021ex31-2_relmada.htm f10k2021ex32-1_relmada.htm f10k2021ex32-2_relmada.htm rlmd-20211231.xsd rlmd-20211231_cal.xml rlmd-20211231_def.xml rlmd-20211231_lab.xml rlmd-20211231_pre.xml

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/07/22  Relmada Therapeutics, Inc.        S-3ASR      4/07/22    6:880K                                   EdgarAgents LLC/FA

26 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/10/21  Relmada Therapeutics, Inc.        10-Q        6/30/21   54:3.4M                                   EdgarAgents LLC/FA
 3/24/21  Relmada Therapeutics, Inc.        10-K       12/31/20   65:4.7M                                   EdgarAgents LLC/FA
 8/12/20  Relmada Therapeutics, Inc.        S-3                    3:499K                                   EdgarAgents LLC/FA
 5/15/20  Relmada Therapeutics, Inc.        10-Q        3/31/20   54:2.7M                                   EdgarAgents LLC/FA
 3/09/20  Relmada Therapeutics, Inc.        8-K:1,5,9   3/06/20    2:33K                                    EdgarAgents LLC/FA
 1/10/20  Relmada Therapeutics, Inc.        8-K:1,5,9   1/09/20    4:294K                                   EdgarAgents LLC/FA
12/26/19  Relmada Therapeutics, Inc.        8-K:5,8,9  12/19/19    6:200K                                   EdgarAgents LLC/FA
12/03/19  Relmada Therapeutics, Inc.        8-K:1,8,9  11/27/19    6:7.7M                                   EdgarAgents LLC/FA
11/13/19  Relmada Therapeutics, Inc.        10-Q        9/30/19   56:2.7M                                   EdgarAgents LLC/FA
 9/27/19  Relmada Therapeutics, Inc.        8-K:3,5,9   9/26/19    3:254K                                   EdgarAgents LLC/FA
 5/15/19  Relmada Therapeutics, Inc.        10-Q        3/31/19   66:5M                                     EdgarAgents LLC/FA
 2/13/19  Relmada Therapeutics, Inc.        10-Q       12/31/18   62:2.9M                                   EdgarAgents LLC/FA
11/13/18  Relmada Therapeutics, Inc.        10-Q        9/30/18   61:3.2M                                   EdgarAgents LLC/FA
 5/14/18  Relmada Therapeutics, Inc.        10-Q        3/31/18   62:3M                                     EdgarAgents LLC/FA
 2/12/18  Relmada Therapeutics, Inc.        10-Q       12/31/17   62:2.9M                                   EdgarAgents LLC/FA
 1/19/18  Relmada Therapeutics, Inc.        8-K:1,9     1/16/18    4:247K                                   EdgarAgents LLC/FA
 9/28/17  Relmada Therapeutics, Inc.        10-K        6/30/17   71:5.1M                                   EdgarAgents LLC/FA
11/25/15  Relmada Therapeutics, Inc.        8-K:5,9    11/20/15    2:151K                                   EdgarAgents LLC/FA
 8/07/15  Relmada Therapeutics, Inc.        8-K:1,5,9   8/03/15    8:532K                                   EdgarAgents LLC/FA
 7/16/15  Relmada Therapeutics, Inc.        8-K:5,8,9   7/14/15    4:147K                                   EdgarAgents LLC/FA
12/09/14  Relmada Therapeutics, Inc.        S-1/A                 65:10M                                    EdgarAgents LLC/FA
 9/09/14  Relmada Therapeutics, Inc.        10-KT       6/30/14   65:8.3M                                   EdgarAgents LLC/FA
 6/02/14  Relmada Therapeutics, Inc.        8-K:5,9     5/30/14    2:574K                                   EdgarAgents LLC/FA
 5/27/14  Relmada Therapeutics, Inc.        8-K:1,2,3,4 5/20/14   93:13M                                    EdgarAgents LLC/FA
 5/19/14  Relmada Therapeutics, Inc.        8-K:3,9     5/14/14    2:46K                                    Clark Corp Law Group LLP
11/13/12  Relmada Therapeutics, Inc.        S-1        11/09/12    5:644K                                   Clark Corp Law Group LLP